Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat.

Abstract

PURPOSE:

Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartan medoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome.

METHODS:

Male SHROB were treated with vehicle or AZL-M orally for 56 days. Vehicle treated normotensive Wistar-Kyoto (WKY) rats served as controls. The effects of AZL-M on kidney injury, vascular endothelial and heart functions, lipid profile, and glucose tolerance were assessed.

RESULTS:

AZL-M demonstrated anti-hypertensive effects along with markedly improved vascular endothelial function in SHROB. In these rats, AZL-M demonstrates strong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB.

CONCLUSION:

Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.

• Authors: Md Abdul Hye Khan, Jan Neckář, Breana Cummens, Geneva M Wahl, John D Imig
• Journal: Cardiovascular drugs and therapy (Cardiovasc Drugs Ther) Vol. 28 Issue 4 Pg. 313-22 (Aug 2014) ISSN: 1573-7241 [Electronic] United States
• PMID: 24842561 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antihypertensive Agents
• Benzimidazoles
• Blood Glucose
• Insulin
• Oxadiazoles
• Protective Agents
• Triglycerides
• Cholesterol
• azilsartan medoxomil

Topics

• Animals
• Antihypertensive Agents (pharmacology, therapeutic use)
• Benzimidazoles (pharmacology, therapeutic use)
• Blood Glucose (analysis)
• Body Weight (drug effects)
• Cholesterol (blood)
• Disease Models, Animal
• Heart (drug effects)
• Hypertension (blood, drug therapy, pathology)
• Hypertrophy, Left Ventricular (blood, drug therapy, pathology)
• In Vitro Techniques
• Insulin (blood)
• Kidney (drug effects, pathology)
• Male
• Mesenteric Arteries (drug effects, physiology)
• Myocardium (pathology)
• Obesity (blood, drug therapy, pathology)
• Oxadiazoles (pharmacology, therapeutic use)
• Protective Agents (pharmacology, therapeutic use)
• Rats, Inbred WKY
• Triglycerides (blood)
• Vasodilation (drug effects)